Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB) announced the grant of inducement awards to Mark Tucker, PhD, as part of his appointment as Senior Vice President, Quality. This was approved by the independent board on April 25, 2022. Dr. Tucker received an option to purchase 120,000 shares of common stock at an exercise price of $0.57, along with a restricted stock unit for 60,000 shares. Both awards will vest over four years based on continued employment. Solid Biosciences focuses on therapies for Duchenne muscular dystrophy, including its gene therapy candidates SGT-001 and SGT-003.

Solid Biosciences Inc. (Nasdaq: SLDB) has announced participation in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 a.m. ET. Ilan Ganot, CEO, and Carl Morris, Chief Scientific Officer, will represent the company. A live webcast will be available on the investor relations website, with a replay accessible after the event. Solid Biosciences is dedicated to developing transformative treatments for Duchenne muscular dystrophy, focusing on gene therapy candidates SGT-001 and SGT-003.

Solid Biosciences (Nasdaq: SLDB) announced its participation in two significant conferences focused on Duchenne muscular dystrophy. At the ASGCT Annual Meeting (May 16-19, 2022), Chief Scientific Officer Carl Morris will present data from the Phase I/II IGNITE DMD clinical trial of SGT-001 gene therapy, including updated long-term outcomes. Following this, Morris will attend the CureDuchenne 2022 FUTURES National Conference (May 27-29, 2022) to discuss advancements in gene therapy. For more details, visit their website.

Solid Biosciences (Nasdaq: SLDB) announced updates regarding programs SGT-001 and SGT-003 aimed at treating Duchenne muscular dystrophy. The company will transition SGT-001 to a commercially scaled manufacturing process, while SGT-003's Investigational New Drug (IND) submission is anticipated in early 2023. Financial results showed a net loss of $25.3 million for Q1 2022, up from $16.9 million in the prior year. Collaboration revenue decreased to $1.9 million. The company plans to streamline operations, reducing its workforce by 35% to extend funding through Q2 2024.

Solid Biosciences (Nasdaq: SLDB) is set to release its first quarter 2022 financial results on April 27, 2022, before market opening. A conference call will follow at 8:00 a.m. ET to discuss results and updates on the SGT-001 and SGT-003 pipeline programs targeting Duchenne muscular dystrophy. The call will be accessible via a live webcast on the company’s website and through dial-in options for participants.

Solid Biosciences (Nasdaq: SLDB) reported positive two-year efficacy and safety data from the high dose cohort (2E14 vg/kg) of its IGNITE DMD Phase I/II clinical trial, showing sustained or improved motor and pulmonary function in patients treated with SGT-001. The company also noted positive 90-day biopsy results indicating microdystrophin expression consistent with prior patients. Financially, Solid ended 2021 with $207.8 million in cash, funding operations into Q3 2023. Collaboration revenue reached $13.6 million for 2021, up from zero in 2020.

Solid Biosciences (Nasdaq: SLDB) announced participation in a fireside chat at the 11th Annual Global Healthcare Conference on February 17, 2022, at 4:20 pm ET. The chat will feature Joel Schneider, PhD, COO, and Carl Morris, PhD, CSO.

A live webcast will be accessible on the company's investor relations website. Solid Biosciences aims to develop transformative treatments for Duchenne muscular dystrophy, focusing on correcting the underlying mutation with gene therapy candidates SGT-001 and SGT-003.

Solid Biosciences (Nasdaq: SLDB) has announced significant advancements in its Duchenne muscular dystrophy (DMD) programs. The company plans to dose more patients in the IGNITE DMD Phase I/II clinical trial for its gene therapy SGT-001 and aims to submit an IND for the next-generation therapy SGT-003 in early 2023. Additionally, Solid ends 2021 with approximately $210 million in cash and investments. Ian F. Smith, previously Chair of the Board, will assume the role of Executive Chair to support the company’s strategic initiatives.

Solid Biosciences (Nasdaq: SLDB), a company dedicated to therapies for Duchenne muscular dystrophy, announced that CEO Ilan Ganot will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 am ET. A Q&A session will follow the presentation. Institutional investors can book meetings with management through their J.P. Morgan representatives. A live webcast will be available on the company’s Investors page, along with an archived replay for 30 days.